Evaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid.

Abstract

A randomized, double-blind study was performed comparing ciprofloxacin in a 500-mg single dose with 1,000 mg (500-mg doses given 12 h apart) for the treatment of chancroid in Thailand. Haemophilus ducreyi was isolated from 87 (48%) of 180 men with a clinical diagnosis of chancroid. For men with ulcers that were culture positive for H. ducreyi, rates of cure were 100% in the 500-mg group and 98% in the 1,000-mg group. For men with ulcers that were culture negative for H. ducreyi, rates of cure were 93% in the 500-mg group and 96% in the 1,000-mg group. The MIC of ciprofloxacin for 50% of isolates among 85 isolates of H. ducreyi was 0.007 micrograms/ml (range, 0.002 to 0.03 micrograms/ml). No significant adverse effects were detected in either group. These data indicate that both of these treatment regimens are equally effective therapies for chancroid in Thailand.

• Authors: L Bodhidatta, D N Taylor, A Chitwarakorn, K Kuvanont, P Echeverria
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 32 Issue 5 Pg. 723-5 (May 1988) ISSN: 0066-4804 [Print] United States
• PMID: 3293526 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Ciprofloxacin

Topics

• Adult
• Chancroid (drug therapy)
• Ciprofloxacin (administration & dosage, pharmacology, therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Drug Administration Schedule
• Follow-Up Studies
• Haemophilus ducreyi (drug effects)
• Humans
• Male
• Middle Aged
• Random Allocation